Divozilimab clinical trials
How each study uses divozilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the divozilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Divozilimab
- 4
Studies by the year they started
4 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2022 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
BCD-256 (1)
Studies
Open first, then newest update. How each study uses divozilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus ErythematosusRecruitingPhase 1BiocadNCT07136389Written as Divozilimab
- Clinical Study of Divozilimab in Patients With Systemic SclerodermaActive, not recruitingPhase 3BiocadNCT05726630Written as Divozilimab
- An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCADCompletedPhase 3BiocadNCT06987851Written as Divozilimab
- Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)Active, not recruitingPhase 3BiocadNCT05730699Written as divozilimab
Codes
What other systems call divozilimab · ClinicalTrials.gg INT014274
- UNII (FDA) 13ZEQ1M5MLDIVOZILIMABOne source FDA
- NCI Thesaurus C175772DivozilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 13ZEQ1M5ML | DIVOZILIMAB | One source FDA |
| NCI Thesaurus | C175772 | Divozilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.